An Open-Label, Multicenter, Phase 1b/2 Study of the Safety andEfficacy of KRT-232 When Administered Alone and inCombination With Low-Dose Cytarabine (LDAC) or Decitabine inPatients With Acute Myeloid Leukemia (AML)
MD Anderson Study Status
KRT-232, Cytarabine, Decitabine
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, when administered alone and in combination with low-dose cytarabine (LDAC) or Decitabine for the treatment of adults with Acute Myeloid Leukemia (AML) and AML secondary to myeloproliferative neoplasms (MPN). Participants must be relapsed/refractory (having failed prior therapy) and will be assigned to receive monotherapy (KRT-232 alone) or combination therapy (KRT-232 with LDAC or KRT-232 with Decitabine).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Relapsed or Refractory Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.